What is the recommended dosage for CJC-1295 (no DAC) / Ipamorelin Protocol?

Research protocols for CJC-1295 (no DAC) / Ipamorelin Protocol: General health optimization: 200 mcg each (0.2mL if 1mg/mL), Once daily before bed via SubQ. Enhanced GH pulsatility: 100-150 mcg each (0.1-0.15mL if 1mg/mL), Twice daily (AM + before bed) via SubQ. Performance enhancement: 250 mcg each (0.25mL if 1mg/mL), Once daily before bed via SubQ. Recovery optimization: 300 mcg each (0.3mL if 1mg/mL), Once daily before bed via SubQ. Conservative approach: 150 mcg each (0.15mL if 1mg/mL), 5 days per week via SubQ.

How to Reconstitute CJC-1295 (no DAC) / Ipamorelin Protocol?

Materials needed: Bacteriostatic water (BAC water), Insulin syringes (29-31 gauge), Alcohol swabs, CJC-1295 / Ipamorelin lyophilized powder vial(s). Steps: 1. Allow vial(s) to reach room temperature (15-20 minutes) 2. Clean vial top(s) with alcohol swab and allow to dry 3. Calculate required bacteriostatic water volume using the calculator below 4. Draw calculated volume of bacteriostatic water into syringe 5. Inject water slowly down the inside wall of the vial (never directly onto powder) 6. Gently swirl until powder completely dissolves (never shake) 7. Solution should be clear - discard if cloudy or contains particles 8. Store reconstituted solution in refrigerator at 2-8°C 9. Administer 2-3 hours after last meal, 30-60 minutes before bed 10. Rotate subcutaneous injection sites (abdomen, thigh, upper arm) to prevent tissue issues

Where do you inject CJC-1295 (no DAC) / Ipamorelin Protocol?

CJC-1295 (no DAC) / Ipamorelin Protocol injection sites: Subcutaneous. Timing: Once daily: 30-60 min before bed. Twice daily: morning (fasted) + before bed. Maintain 2-3 hour fast before each dose.

What is the cycle length for CJC-1295 (no DAC) / Ipamorelin Protocol?

The typical cycle length for CJC-1295 (no DAC) / Ipamorelin Protocol is 8-12 weeks on, 4 weeks off recommended to maintain receptor sensitivity. Recommended break between cycles: 4 week minimum breaks help preserve natural GH production and receptor responsiveness.

Can you take CJC-1295 (no DAC) / Ipamorelin Protocol with MK-677?

CJC-1295 (no DAC) / Ipamorelin Protocol and MK-677: Monitor Combination. Both affect GH pathways. Monitor for excessive GH elevation and potential insulin sensitivity changes with combined use..

Can you take CJC-1295 (no DAC) / Ipamorelin Protocol with BPC-157?

CJC-1295 (no DAC) / Ipamorelin Protocol and BPC-157: Compatible. No known interactions. Different mechanisms - GH optimization versus direct tissue repair signaling..

Can you take CJC-1295 (no DAC) / Ipamorelin Protocol with Insulin?

CJC-1295 (no DAC) / Ipamorelin Protocol and Insulin: Monitor Combination. Growth hormone affects insulin sensitivity. Diabetic users require blood glucose monitoring and potential insulin dose adjustments..

Can you take CJC-1295 (no DAC) / Ipamorelin Protocol with Synthetic HGH?

CJC-1295 (no DAC) / Ipamorelin Protocol and Synthetic HGH: Avoid Combination. Redundant mechanisms may cause excessive GH levels and suppress natural pulsatile release patterns..

Can you take CJC-1295 (no DAC) / Ipamorelin Protocol with Thyroid Medications?

CJC-1295 (no DAC) / Ipamorelin Protocol and Thyroid Medications: Requires Timing. Space thyroid medications 4+ hours from GH secretagogues due to potential absorption and metabolic interactions..

Can you take CJC-1295 (no DAC) / Ipamorelin Protocol with Corticosteroids?

CJC-1295 (no DAC) / Ipamorelin Protocol and Corticosteroids: Use Caution. Corticosteroids can blunt GH response. May require higher doses or alternative timing when used together..

What are the side effects of CJC-1295 (no DAC) / Ipamorelin Protocol?

CRITICAL: Test individual peptides separately before using blended protocols if possible. NOTE: No clinical trials have validated specific combination benefits or safety profiles. Use only pharmaceutical-grade peptides with verified certificates of analysis. Monitor blood glucose if diabetic - growth hormone can affect insulin sensitivity. Start with conservative doses (200mcg each) to assess individual tolerance. Discontinue if adverse reactions occur and consider separate testing to identify source. Maintain injection site rotation to prevent lipodystrophy or tissue damage. Regular bloodwork recommended to monitor IGF-1 levels and overall health markers.

How long does CJC-1295 (no DAC) / Ipamorelin Protocol take to work?

Week 1-2: Improved sleep depth and quality. Some users report more vivid dreams. Week 3-4: Enhanced recovery from exercise. Reduced muscle soreness and improved energy. Week 6-8: Gradual body composition changes. Improved skin quality and general well-being. Week 8-12: Optimized benefits if protocol is effective. Individual responses vary significantly. Post-cycle: Some benefits may persist for several weeks due to improved sleep and recovery patterns.

How should you store CJC-1295 (no DAC) / Ipamorelin Protocol?

CJC-1295 (no DAC) / Ipamorelin Protocol should be stored at Refrigerate reconstituted peptides at 2-8°C. Use within 30 days of reconstitution for optimal potency.

When should you stop taking CJC-1295 (no DAC) / Ipamorelin Protocol?

Stop CJC-1295 (no DAC) / Ipamorelin Protocol and consult a healthcare provider if you experience: Persistent joint pain or swelling that may indicate fluid retention; Significant blood glucose changes or diabetic control issues; Unusual fatigue, lethargy, or mood changes that worsen over time; Injection site reactions, infections, or persistent irritation; Numbness or tingling in hands/feet (potential carpal tunnel syndrome); Any signs of accelerated tumor growth if cancer history present.

CJC-1295 (no DAC) / Ipamorelin Protocol - Research, Dosing & Protocols

Did you know? You can suggest edits to improve this peptide information.

Overview

What is CJC-1295 (no DAC) / Ipamorelin Protocol?

A combination protocol using CJC-1295 without DAC (also known as Mod GRF 1-29) and Ipamorelin through complementary receptor mechanisms. CJC-1295 without DAC has a short half-life of 30 minutes to 2 hours, enabling pulsatile GH release that mimics natural physiology. Ipamorelin provides selective GH release without affecting cortisol, ACTH, or prolactin. Note: This protocol uses the no-DAC version specifically for pulsatile release patterns.

Key Benefits

Dual-pathway GH optimization through complementary mechanisms. CJC-1295 without DAC (Mod GRF 1-29) and Ipamorelin both have short half-lives (30 min-2 hours), producing synergistic pulsatile GH spikes that mimic natural physiology without cortisol effects.

Mechanism of Action

CJC-1295 without DAC (Mod GRF 1-29) stimulates GHRH receptors on pituitary somatotrophs, triggering cAMP/PKA-mediated GH synthesis with a short 30-minute to 2-hour half-life. Ipamorelin selectively activates ghrelin receptors (GHSR1a) via Gq/11-linked calcium signaling without affecting ACTH or cortisol pathways. Together, the dual-pathway activation produces amplified, pulsatile GH spikes. Note: Combination benefits are theoretically sound but lack direct clinical validation.

Research Indications

Enhanced protein synthesis

Growth hormone elevation supports muscle protein synthesis and nitrogen retention during training

Improved recovery

Sustained GH patterns may accelerate muscle repair between exercise sessions

Lean mass preservation

GH optimization helps maintain muscle during caloric restriction or aging

Research Protocols

Disclaimer

These are commonly discussed research protocols and not medical advice. Consult a healthcare provider before use.

Dosage protocols for CJC-1295 (no DAC) / Ipamorelin Protocol
Goal	Dose	Frequency	Route
General health optimization	200 mcg each (0.2mL if 1mg/mL)	Once daily before bed	SubQ
Enhanced GH pulsatility	100-150 mcg each (0.1-0.15mL if 1mg/mL)	Twice daily (AM + before bed)	SubQ
Performance enhancement	250 mcg each (0.25mL if 1mg/mL)	Once daily before bed	SubQ
Recovery optimization	300 mcg each (0.3mL if 1mg/mL)	Once daily before bed	SubQ
Conservative approach	150 mcg each (0.15mL if 1mg/mL)	5 days per week	SubQ

Timing

CJC-1295 without DAC has a short 30-minute to 2-hour half-life, similar to Ipamorelin (~2 hours). This enables pulsatile GH release rather than sustained elevation. Once daily (before bed) is convenient; twice daily (AM + PM) better mimics natural GH pulsatility and allows receptor recovery between doses (~6 hours needed for GHS receptor resensitization).

Peptide Interactions

How to Reconstitute

Important

Always use bacteriostatic water (BAC). Sterile technique is essential.

Allow vial(s) to reach room temperature (15-20 minutes)

Clean vial top(s) with alcohol swab and allow to dry

Calculate required bacteriostatic water volume using the calculator below

Draw calculated volume of bacteriostatic water into syringe

Inject water slowly down the inside wall of the vial (never directly onto powder)

Gently swirl until powder completely dissolves (never shake)

Solution should be clear - discard if cloudy or contains particles

Store reconstituted solution in refrigerator at 2-8°C

Administer 2-3 hours after last meal, 30-60 minutes before bed

Rotate subcutaneous injection sites (abdomen, thigh, upper arm) to prevent tissue issues

Quality Indicators

✓

Standard format labeling

Most common: '10mg total: 5mg CJC-1295 + 5mg Ipamorelin' for blended vials, or separate 5mg vials for individual peptides

Format selection guidance

BEGINNERS: Separate vials allow individual tolerance testing. EXPERIENCED: Blended offers convenience but limits dose adjustment

✓

1:1 ratio maintenance

Whether blended or separate, equal amounts of each peptide are recommended for optimal complementary effects

✓

Clear reconstitution

Both formats should dissolve completely clear without particles, cloudiness, or precipitation

✓

Certificate of Analysis

Reputable sources provide COA with purity testing. For blends, should show individual peptide purities

✓

Proper cold chain

Should arrive with cold packs and require immediate refrigeration. Temperature stability is critical

✗

Poor storage indicators

Avoid products with damaged packaging, missing refrigeration, or exposure to heat during shipping

Research limitations

Note: Combination protocols lack peer-reviewed clinical validation compared to individual peptide studies

DAC vs No-DAC clarity

Ensure product is labeled 'CJC-1295 no DAC' or 'Mod GRF 1-29'. The DAC version has different pharmacokinetics (6-8 day vs 30-min half-life) and is NOT interchangeable in this protocol

What to Expect

Week 1-2: Improved sleep depth and quality. Some users report more vivid dreams
Week 3-4: Enhanced recovery from exercise. Reduced muscle soreness and improved energy
Week 6-8: Gradual body composition changes. Improved skin quality and general well-being
Week 8-12: Optimized benefits if protocol is effective. Individual responses vary significantly
Post-cycle: Some benefits may persist for several weeks due to improved sleep and recovery patterns

Side Effects & Safety

CRITICAL: Test individual peptides separately before using blended protocols if possible
NOTE: No clinical trials have validated specific combination benefits or safety profiles
Use only pharmaceutical-grade peptides with verified certificates of analysis
Monitor blood glucose if diabetic - growth hormone can affect insulin sensitivity
Start with conservative doses (200mcg each) to assess individual tolerance
Discontinue if adverse reactions occur and consider separate testing to identify source
Maintain injection site rotation to prevent lipodystrophy or tissue damage
Regular bloodwork recommended to monitor IGF-1 levels and overall health markers

References

CJC-1295 with DAC Clinical Efficacy - Teichman et al. (2006)

Human | 30-60 mcg/kg | 28-49 days | CJC-1295 WITH DAC version

Note: This landmark study used CJC-1295 WITH DAC (5.8-8.1 day half-life), not the no-DAC version used in CJC/IPA protocols. Included for reference on the GHRH analog mechanism, but pharmacokinetics differ significantly from Mod GRF 1-29.

View Study →

Modified GRF 1-29 Pharmacokinetics

Human | Various doses | Short-acting GHRH analog

CJC-1295 without DAC (Mod GRF 1-29) has a half-life of approximately 30 minutes to 2 hours due to lack of albumin-binding DAC. This short duration enables pulsatile GH release patterns preferred for combination protocols with GHRPs like Ipamorelin.

GH Pulsatility Preservation - Ionescu & Frohman (2006)

Human | Continuous monitoring | 14 days | Maintained natural rhythm

Demonstrated CJC-1295 preserves pulsatile GH secretion while increasing basal levels 7.5-fold.

View Study →

Quick Start Guide

Typical Dose

200-250 mcg each peptide once daily, or 100-150 mcg each twice daily

How Often

Once daily before bed, or twice daily (AM + before bed) for enhanced pulsatility

Where to Inject

Subcutaneous

Injection Timing

Once daily: 30-60 min before bed. Twice daily: morning (fasted) + before bed. Maintain 2-3 hour fast before each dose

Effects Timeline

Sleep improvements: 1-2 weeks. Recovery benefits: 2-4 weeks. Body composition: 6-12 weeks

Storage

Refrigerate reconstituted peptides at 2-8°C. Use within 30 days of reconstitution for optimal potency

Cycle Length

8-12 weeks on, 4 weeks off recommended to maintain receptor sensitivity

Break Between

4 week minimum breaks help preserve natural GH production and receptor responsiveness

Community Poll

Question 1 of 10

What is your experience with this compound?

Poll Results

Loading results...

Community Insights

Self-reported by PepPedia users. Not clinical evidence. Health changes reflect all users, including those taking multiple compounds.

Was this helpful?

Your feedback helps us improve PepPedia

Related Peptides

Well Researched

Goal

Dose

Frequency

Route

General health optimization

200 mcg each (0.2mL if 1mg/mL)

Once daily before bed

SubQ

Enhanced GH pulsatility

100-150 mcg each (0.1-0.15mL if 1mg/mL)

Twice daily (AM + before bed)

SubQ

Performance enhancement

250 mcg each (0.25mL if 1mg/mL)

Once daily before bed

SubQ

Recovery optimization

300 mcg each (0.3mL if 1mg/mL)

Once daily before bed

SubQ

Conservative approach

150 mcg each (0.15mL if 1mg/mL)

5 days per week

SubQ

Calculator

What's in your vial?

How much diluent?

What's your dose per injection?

How often will you inject?

Your Recipe

Add — mL diluent

Draw —

CJC-1295 (no DAC) / Ipamorelin Protocol

Overview

What is CJC-1295 (no DAC) / Ipamorelin Protocol?

Key Benefits

Mechanism of Action

Research Indications

Muscle GrowthMost Effective

Enhanced protein synthesis

Improved recovery

Lean mass preservation

Metabolic HealthEffective

Anti AgingModerate

RecoveryModerate

Research Protocols

Peptide Interactions

MK-677Monitor Combination

BPC-157Compatible

InsulinMonitor Combination

Synthetic HGHAvoid Combination

Thyroid MedicationsRequires Timing

CorticosteroidsUse Caution

How to Reconstitute

Quality Indicators

Standard format labeling

Format selection guidance

1:1 ratio maintenance

Clear reconstitution

Certificate of Analysis

Proper cold chain

Poor storage indicators

Research limitations

DAC vs No-DAC clarity

What to Expect

Side Effects & Safety

References

CJC-1295 with DAC Clinical Efficacy - Teichman et al. (2006)

Modified GRF 1-29 Pharmacokinetics

GH Pulsatility Preservation - Ionescu & Frohman (2006)

Quick Start Guide

Community Poll

Poll Results

Community Insights

Was this helpful?

Related Peptides

CJC-1295 (without DAC)

Ipamorelin

Sermorelin

Tesamorelin

Calculator

What's in your vial?

How much diluent?

What's your dose per injection?

How often will you inject?

Your Recipe

Add — mL diluent

Draw —

Calculator

What's in your vial?

How much diluent?

What's your dose per injection?

How often will you inject?

Your Recipe

Add — mL diluent

Draw —

CJC-1295 (no DAC) / Ipamorelin Protocol

Overview

What is CJC-1295 (no DAC) / Ipamorelin Protocol?

Key Benefits

Mechanism of Action

Research Indications

Muscle GrowthMost Effective

Enhanced protein synthesis